Trial NCT02138825

View at ClinicalTrials.gov 
Org. Study IDs: 13605
Secondary IDs: 2010-024332-42

Last trial update was posted on 2017-12-04

MeSH Interventions

Riociguat

MeSH Conditions

Hamman-Rich Syndrome Hypertension Hypertension, Pulmonary Idiopathic Interstitial Pneumonias Lung Diseases, Interstitial Pneumonia Pulmonary Fibrosis

Other Conditions

Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary

Stopping Reasons

Study terminated per recommendation of iDMC. On iDMC request, protocol amended to include 4-month safety follow-up for patients after withdrawal of riociguat.

Limitations And Caveats

The study was prematurely terminated following a recommendation from the independent Data Monitoring Committee, as patients receiving Riociguat showed an increased risk of mortality and serious adverse events as compared to patients receiving Placebo

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID